Highlights of Precision Medicine, Genetics, Epigenetics and Artificial Intelligence in Pompe Disease
Open Access
- 17 January 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (2) , 757
Abstract
Pompe disease is a neuromuscular disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA), which leads to lysosomal glycogen accumulation and progressive development of muscle weakness. Two distinct isoforms have been identified. In the infantile form, the weakness is often severe and leads to motor difficulties from the first few months of life. In adult patients, the progression is slower but can still lead to significant loss of mobility. The current inherent difficulties of the disease lie in both early diagnosis and the use of biomarkers. Given that this is a multifactorial disease, a number of components may exert an influence on the disease process; from the degree of pre-ERT (enzyme replacement therapy) muscle damage to the damaged autophagic system and the different pathways involved. What methodology should be employed to study the complex characteristics of Pompe disease? Our approach relies on the application of genetic and epigenetic knowledge, with a progression from proteomics to transcriptomics. It is also becoming increasingly evident that artificial intelligence is a significant area of interest. The objective of this study is to conduct a comprehensive review of the existing literature on the known data and complications associated with the disease in patients with disorders attributed to Pompe disease.Keywords
This publication has 78 references indexed in Scilit:
- Quantitative Systems Pharmacology‐Based Digital Twins Approach Supplements Clinical Trial Data for Enzyme Replacement Therapies in Pompe DiseaseClinical Pharmacology & Therapeutics, 2024
- High‐risk screening for late‐onset Pompe disease in China: An expanded multicenter studyJournal of Inherited Metabolic Disease, 2024
- Getting the Dose Right in Drug Development for Rare Diseases: Barriers and EnablersClinical Pharmacology & Therapeutics, 2024
- Development of a rapid simultaneous assay of two urinary tetrasaccharide metabolites using differential ion mobility and tandem mass spectrometry and its application to patients with glycogen storage disease (type Ib and II)Analytical and Bioanalytical Chemistry, 2023
- Screening data from 19 patients with late‐onset Pompe disease for a phase I clinical trial of AAV8 vector‐mediated gene therapyJIMD Reports, 2023
- Classic infantile‐onset Pompe disease with histopathological neurologic findings linked to a novel GAA gene 4 bp deletion: A case studyMolecular Genetics & Genomic Medicine, 2022
- Bright tongue sign in patients with late-onset Pompe diseaseJournal of Neurology, 2019
- Enzyme replacement therapy for infantile-onset Pompe diseaseCochrane Database of Systematic Reviews, 2017
- Next generation sequencing detection of late onset pompe diseaseMuscle & Nerve, 2016
- Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow‐upJournal of Inherited Metabolic Disease, 2015